• News and stories
  • Careers
  • Events
  • Contact us
  • Donate
  • 한국어
ivi-logox2ivi-logox2ivi-logo-1ivi-logo-1
  • Who We Are
    • Vision & Mission
    • Why Vaccines
    • IVI in Brief
    • History
    • Director General’s Message
    • Policies
      • Gender equality
      • Environmental sustainability
    • Leadership
      • Board of Trustees
      • Scientific Advisory Group
      • Executive Leadership Team
    • Senior Management
    • Our Partners
    • FAQ
  • What We Do
    • Overview
    • Discover
    • Develop
    • Deliver
    • Build Capacity
    • Disease Areas
      • Cholera
      • Typhoid
      • Dengue
      • MERS
      • Schistosomiasis
      • Chikungunya
      • COVID-19
      • AMR
        • RADAAR
      • Other
  • Where We Work
    • Overview Map
    • IVI Member States
  • Our Impact
    • Journal Publications
    • International Vaccinology Course
    • News and stories
    • Annual Report & Financial Statement
✕

Statement of Clarification

  • Home
  • News Announcements
  • Statement of Clarification

Statement of Clarification

The International Vaccine Institute (IVI) would like to make clear that Director General Jerome Kim and IVI do NOT endorse or work with CVDchain.

 

Contrary to www.cvdchain.vip, Dr. Jerome Kim is not a member of the CVDchain “Team.” CVDchain has used Director General Jerome Kim’s name and photograph without consent.

 

IVI has filed an official complaint with www.cvdchain.vip domain registrar Chengdu West Dimension Digital Technology Co., Ltd., asking for the removal of Director General Jerome Kim’s name and photograph from the website.

 

IVI encourages the general public to exercise caution and practice due diligence when considering the claims of third-party sources. Director General Jerome Kim and IVI hold no legal responsibility for the claims or transactions of CVDchain. We appreciate your understanding.

Related posts

SKYCovione™ is South Korea's first homegrown vaccine to achieve licensure. Photo courtesy of SK bioscience.

07/02/2022

SK bioscience’s COVID-19 vaccine approved for use by Republic of Korea


Read more
  • News and stories
  • Press Releases
  • Announcements
  • IVI in the Media
  • Blog
  • Newsletters

Subscribe to usemail addressSubscribe

Social Media

Stay Connected

Who We Are

  • Vision & Mission
  • Why Vaccines
  • IVI in Brief
  • History
  • Director General’s Message
  • Policies
    • Gender equality
    • Environmental Sustainability
  • State Parties/Signatories
  • Leadership
    • Board of Trustees
    • Scientific Advisory Group
    • Executive Leadership Team
  • Senior Management
  • Our Partners

What We Do

  • Overview
  • Discover
  • Develop
  • Deliver
  • Build Capacity
  • Disease Areas
    • Cholera
    • Typhoid
    • Dengue
    • MERS
    • Schistosomiasis
    • Chikungunya
    • COVID-19
    • Other

Where We Work

  • Overview map
  • IVI Member State Relations

Our Impact

  • Journal Publications
  • International Vaccinology Course
  • News and stories
  • Annual Reports & Financial Statement

Donate

  • Korea Support Committee for IVI (KSC)
Copyright 2022 International Vaccine Institute. All Rights Reserved.
    • No translations available for this page
    • News and stories
    • Careers
    • Events
    • Contact us
    • Donate
    • 한국어